Press Release|

SHL Medical enters the 'New Normal'

Newnormal Covid19 1200x630 (1)

Since January 2020, SHL Medical has been closely monitoring the global effect of the Coronavirus 2019 (COVID-19).

We took early measures to protect the health and safety of our staff and ensure the continuity of drug delivery products for our customers and end-users during the crisis. Due to our manufacturing and production hub location in Taiwan, with its worldbeating epidemic response, we were able to continue production of all our devices as normal and worked with both suppliers and freight agencies to ensure uninterrupted business over the last six months.

Now, SHL Medical is keeping a step ahead in the next phase of the challenge. As we face the ‘new normal’ across all our sites, which are all at various stages, we are implementing measures that look forward to an evolved way of working.

Our manufacturing was not impacted during the crisis, and in fact, rose substantially. This will not change. A testament to our ongoing internal assessment and constant vetting of all design, quality, and manufacturing systems is the updating of processes and procedures, such as those to be compliant with the new European Union Medical Device Regulation (EU MDR). Although subsequently, the EU extended the MDR deadline, SHL Medical was and remains, ahead of the game in preparation for the new regulations.

As always, we maintain continuous monitoring and ongoing risk assessment and work closely with suppliers and partners to ensure the production and delivery of products.

Our staff are all educated and informed on the existing risks and the needs for continued hygiene and physical distance practice. The period of working from home for many staff has seen positive benefits of rapidly becoming familiar with our new digital collaboration tools, rolled out globally just before the pandemic hitVideo conferencing and remote collaborative working have become second nature to our staff across sites.

Just as we acted early in the pandemic to protect our customers, business and staff, we are now well-prepared to move forward together into the new normal.

Please contact us with any further enquiries you may have on the above. 

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News